Health condition · Clinically reviewed
Barrett’s oesophagus, metaplasia, surveillance and modern endoscopic treatment.
Intestinal-type metaplasia in the lower oesophagus from chronic reflux. Regular surveillance and endoscopic therapy for dysplasia prevent progression to cancer.
Why trust this guide
- 01
Clinically reviewed
Written by our editorial team and reviewed by a registered UK clinician before publication.
- 02
Sourced from guidance
Every claim is checked against BSG, NICE or peer-reviewed sources you can see at the end.
- 03
Current for 2026
Reflects current UK guidance on surveillance intervals, RFA, EMR and endoscopic management of dysplasia.
Key facts
Barrett’s oesophagus at a glance.
The essentials, in plain English — what Barrett’s is, how it is monitored, and how dysplasia is treated endoscopically.
-
Definition
Intestinal-type metaplasia at the lower oesophagus, confirmed on endoscopic biopsy.
-
Nature
A precancerous condition — but the progression rate to cancer is low.
-
Surveillance
Interval endoscopy depends on segment length (Prague C&M) and presence of dysplasia.
-
Acid control
High-dose proton pump inhibitor (PPI) therapy is recommended long-term.
-
Ablation
Radiofrequency ablation (RFA) is standard treatment for confirmed dysplasia.
-
Early cancer
Endoscopic mucosal resection (EMR) treats visible lesions and early adenocarcinoma.
Why this guide matters
Precancerous, but very treatable.
Barrett’s is a manageable condition when found early and monitored properly — the three points below shape everything that follows.
-
Surveillance changes outcomes
Interval endoscopy catches dysplasia before it becomes cancer — the whole reason for follow-up.
-
RFA and EMR are highly effective
Modern endoscopic therapy removes dysplasia and early cancer without major surgery.
-
Acid control still matters
High-dose PPI therapy supports mucosal healing and reduces reflux injury long-term.
How the diagnosis is made
From first endoscopy to a surveillance plan.
The steps a UK upper GI team will normally follow — so you know what to expect and why.
Phase 1 · Recognising
History and index endoscopy
Phase 2 · Confirming
Histology, Prague C&M and dysplasia grading
Phase 3 · Managing
MDT and surveillance
- 01
Recognising
Symptom and reflux history
Long-standing heartburn, regurgitation and risk factors — obesity, male sex, smoking, age over 50.
- 02
Recognising
Upper GI endoscopy + biopsies
Direct visualisation of the lower oesophagus with targeted and quadrantic biopsies per Seattle protocol.
- 03
Confirming
Confirm intestinal metaplasia
Histology must show intestinal-type columnar epithelium with goblet cells to confirm Barrett’s.
- 04
Confirming
Prague classification (C&M)
The circumferential (C) and maximal (M) extent of Barrett’s segment is recorded in centimetres.
- 05
Confirming
Dysplasia grading
No dysplasia, indefinite, low-grade or high-grade — confirmed by a second expert GI pathologist.
- 06
Managing
Multidisciplinary review
Any dysplasia is discussed at an upper GI MDT to agree endoscopic therapy or surgery.
- 07
Managing
Surveillance interval plan
A personalised follow-up schedule — usually 3-5 yearly for non-dysplastic Barrett’s.
Typical pathway: index endoscopy to a settled surveillance plan within weeks.
Symptoms
What Barrett’s actually feels like.
Barrett’s itself is usually silent — most symptoms come from the reflux that caused it. These are the features that matter most.
-
Chronic reflux history
Years of heartburn or regurgitation — Barrett’s itself is usually silent.
-
Dysphagia
Food catching or sticking — always warrants prompt endoscopy.
-
Black tarry stools
Melaena suggests upper GI bleeding — attend A&E without delay.
-
Anaemia
Iron-deficiency anaemia with reflux — investigate for chronic blood loss.
-
Weight loss (concerning)
Unintentional weight loss with reflux is a red-flag combination.
-
Post-cardio hospitalisation
Recent cardiac events can complicate anti-reflux and endoscopic decisions.
-
Prior treatment failure
Recurrent metaplasia after previous ablation needs re-treatment planning.
-
Red flag: dysphagia + weight loss
Together these mandate an urgent 2-week-wait endoscopy referral.
Treatment
How Barrett’s is treated in the UK.
Acid control and surveillance for most, endoscopic therapy for dysplasia, and surgery only for invasive cancer.
-
High-dose PPI
Long-term acid suppression reduces reflux injury and supports mucosal healing after therapy.
-
Lifestyle
Weight loss, no late meals, reduced alcohol and stopping smoking all measurably reduce reflux burden.
-
Surveillance endoscopy
Repeat endoscopy with biopsies at 3-5 yearly intervals for non-dysplastic Barrett’s.
-
Chromoendoscopy / advanced imaging
Narrow-band imaging or dye-spray to detect subtle dysplasia during surveillance.
-
Endoscopic mucosal resection (EMR)
Removes visible nodules and early cancer — provides tissue for accurate staging.
-
Radiofrequency ablation (RFA)
Thermal ablation of dysplastic Barrett’s mucosa, allowing normal squamous epithelium to regrow.
-
Cryotherapy
An alternative ablative option for selected residual or recurrent Barrett’s segments.
-
Oesophagectomy
Reserved for invasive cancer not amenable to endoscopic therapy — a specialist upper GI operation.
What this guide is based on
The sources behind every claim on this page.
UK national guidance and specialist society standards, current at the time of last review.
Key references
Guidelines and standards we relied on.
A quiet reminder
This guide is for information, not medical advice.
Your clinician knows your history and can tell you which parts apply to you. If in doubt, contact them.
-
British Society of Gastroenterology. Barrett’s oesophagus guideline.
-
NICE. Oesophago-gastric cancer: assessment and management (NG83).
-
European Society of Gastrointestinal Endoscopy. Barrett’s management guidance.
-
Cancer Research UK. Oesophageal cancer: risks and causes.
Red flags
When Barrett’s stops being routine.
Most Barrett’s is managed calmly with surveillance. These are the situations that need faster action.
-
Dysphagia + weight loss
Together these mandate an urgent 2-week-wait endoscopy referral.
-
High-grade dysplasia
Requires prompt endoscopic therapy at a specialist Barrett’s centre.
-
Intramucosal cancer
Early adenocarcinoma — usually treated with EMR followed by ablation.
-
Bleeding after ablation
Fresh haematemesis or melaena following RFA — urgent review.
-
Stricture post-treatment
Progressive dysphagia after ablation may need endoscopic dilatation.
-
Adenocarcinoma diagnosis
Confirmed invasive cancer — refer to upper GI MDT without delay.
-
Post-op leak
After oesophagectomy — fever, chest pain or tachycardia needs immediate surgical review.
-
Aspiration
Reflux with new cough, fevers or breathlessness — assess for aspiration pneumonia.
-
Recurrent metaplasia after ablation
Barrett’s that returns after RFA needs re-treatment and closer surveillance.
Living with it
A long-term condition, managed quietly and well.
Four things that make the biggest difference — acid control, surveillance, lifestyle, and follow-up after any ablation.
A quiet reminder
Consistency beats intensity, every time.
Small, steady habits — kept up for years — do more than a heroic week that does not last.
- 01 Acid control
PPIs are usually lifelong
High-dose acid suppression reduces reflux injury and supports healing after any ablation.
- 02 Surveillance
Keep every scope appointment
Regular endoscopy is what turns Barrett’s from a worry into a managed, low-risk condition.
- 03 Lifestyle
Weight and meal timing matter
The same measures that help reflux — weight loss, no late meals — reduce Barrett’s progression risk.
- 04 After RFA
Follow-up does not stop
Even after successful ablation, surveillance continues because recurrence can occur.
Frequently asked
Everything we get asked about Barrett’s oesophagus.
Quick answers on progression risk, Prague C&M, RFA, EMR and surveillance intervals.
-
Is Barrett’s oesophagus cancer?
No — Barrett’s itself is not cancer. It is a change in the lining of the lower oesophagus that carries a small increased risk of oesophageal adenocarcinoma over time.
-
What is the risk of progression?
For non-dysplastic Barrett’s, the annual risk of progression to cancer is low — around 0.3% per year. Risk rises with dysplasia and longer segments, which is why surveillance intervals differ.
-
What is the Prague C&M classification?
A standardised way of recording how much oesophagus is affected: C is the circumferential extent and M is the maximum length of Barrett’s in centimetres.
-
What is RFA?
Radiofrequency ablation uses controlled heat delivered through an endoscope to remove dysplastic Barrett’s mucosa, allowing normal squamous lining to regrow.
-
What is EMR?
Endoscopic mucosal resection removes visible nodules or areas of early cancer through the endoscope, providing tissue for accurate staging and often curative treatment.
-
How often will I need endoscopy?
Typically 3-5 yearly for non-dysplastic Barrett’s. Intervals shorten with any dysplasia, and endoscopic therapy is offered for confirmed dysplasia or early cancer.
Related content
Keep reading.
-
Endoscopy
The core test that diagnoses and monitors Barrett’s.
Learn more -
24-hour pH monitoring
Quantifies reflux burden when the picture is unclear.
Learn more -
Endoscopic ultrasound
Stages early oesophageal cancer before treatment.
Learn more -
All conditions
Browse the full library of clinically reviewed guides.
Learn more